NEW YORK (GenomeWeb News) – Danaher today said that revenues in the fourth quarter rose nearly 6 percent year over year paced by its Life Sciences and Diagnostics segment.

For the three months ended Dec. 31, 2012, the company posted total revenues of $4.98 billion, up from $4.72 billion in the year-ago period, and beating the consensus Wall Street estimate of $4.81 billion.

Core revenues increased 3.5 percent year over year during the quarter, while acquisitions added 3 percent growth, and the impact of currency translation cut growth by 1 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.